Followers | 145 |
Posts | 6539 |
Boards Moderated | 0 |
Alias Born | 03/13/2014 |
Friday, November 15, 2019 7:59:57 AM
(Alliance News) - Motif Bio PLC said Monday it agreed to settle all obligations with its former clinical research organisation without requiring any further payments.
For the six months ended June, Motif had recognised an additional USD2.4 million expense to settle this dispute. This recognition will be reversed following the agreement.
Shares in Motif Bio were 8.3% lower at 0.43 pence in London on Monday.
In October, Motif Bio announced a major restructure which would see its sell its main listeria-fighting drug iclaprim. This followed US regulators requiring iclaprim to pass further hurdles to secure new drug application status.
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM